PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for fo	m 1449A/PTO				Complete if Known		
INFORM	ATION DICC		UDE		Application Number	10/822,053	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Filing Date	April 8, 2004	
SIAILI	CNI DI API	PLIC	AN I		First Named Inventor	Robert Graham Feldman	
(4	ise as many sheet	s as ne	cessary)		Art Unit	1645	<del></del>
<u> </u>					Examiner Name	NAVARRO	
Sheet	1	of		3	Attorney Docket Number	G.IF-44D1	

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
~	U1	US-5,876,931	03-02-1999	Holden	All			
~~	U2	US-5,643,579	07-01-1997	Hung et al.	All			
	U3	US-						
	_U4	US-						
	<u>U5</u>	US-						
	_ U6	US-						
	U7	US-						
	U8	US-						
	U9	US-						

		FOREIGN	PATENT DOCL	<b>IMENTS</b>		
		Foreign Patent Document			Dane Caluma Harr	Г
Examiner Initials*	Cite No. 1	Country Code 3 - Number 4 - Kind Code <sup>6</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	  -
m	F1	EPO 0889120 B1	01-07-1999	Microscience Limited	Ail	
~~	F2	WO 00/14240	03-16-2000	CREATOGEN BIOSCIENCES GMBH	All	
	F3					⇈
	F4					$\vdash$
	F5					
	F6		5.2			
	F7					1

Examiner Signature MARK NAVARAGO	Date Considered 11/29/05
----------------------------------	--------------------------

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kind Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, OSPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 nours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.

Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

3

Sheet

Complete if Known					
Application Number	10/822,053				
Filing Date	April 8, 2004				
First Named Inventor	Robert Graham Feldman				
Group Art Unit	1645				
Examiner Name	NAVAROLO				
Attorney Docket Number	GJE-44D1				

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the ltem (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
~	R1	MEDINA, E. et al. "Pathogenicity Island 2 Mutants of Salmonella typhimurium Are Efficient Carriers for Heterologous Antigens and Enable Modulation of Immune Responses", Infection and Immunity, 1999, pp. 1093-1099, Vol. 67, No. 3.					
~	R2	VALENTINE, P.J. et al. "Identification of Three Highly Attenuated Salmonella typhimurium Mutants That Are More Immunogenic and Protective in Mice than a Prototypical eroA Mutant", Infection and Immunity, 1998, pp. 3378-3383, Vol. 66, No. 7.					
$\sim$	R3	HENSEL, M. et al. "Genes Encoding Putative Effector Proteins of the Type III Secretion System of Salmonella Pathogenicity Island 2 are Required for Bacterial Virulence and Proliferation in Macrophages", Molecular Microbiology, 1998, pp. 163-174, Vol. 30, No. 1.					
~	R4	HENSEL, M. et al. "Analysis of the Boundaries of Salmonella Pathogenicity Island 2 and the Corresponding Chromosomal Region of Escherichia coli K-12", Journal of Bacteriology, 1997, pp. 1105-1111, Vol. 179, No. 4.					
~	R5	HENSEL, M. et al. "Functional Analysis of ssaJ and ssaK/U Operon, 13 Genes Encoding Components of the Type III Secretion Apparatus of Salmonella Pathogenicity Island 2", Molecular Microbiology, 1997, pp. 155-167, Vol. 24, No. 1.					
~	R6	SHEA, J.E. et al. "Influence of the Salmonella typhimurium Pathogenicity Island 2 Type III Secretion System on Bacterial Growth in the Mouse", Infection and Immunity, 1999, pp. 213-219, Vol. 67, No. 1.					
~	R7	SHEA, J.E. et al. "Identification of a Virulence Locus Encoding a Second Type III Secretion System in Salmonella typhimurium", Proc. Natl. Acad. Sci. USA, 1996, pp. 2593-2597, Vol. 93.					
$\sim$	R8	CHATFIELD, S. N. et al. "Construction of a Genetically Defined Salmonella typhi Ty2 aroA, aroC Mutant for the Engineering of a Candidate Oral Typhoid-Tetanus Vaccine", Vaccine, 1992, pp. 53-60, Vol. 10, No. 1.					
~	R9	LEVINE, M.M. et al. "Attenuated Salmonella as Live Oral Vaccines Against Typhold Fever and as Live Vectors", Journal of Biotechnology, 1996, pp. 193-196, Vol. 44, No. 1-3.					
<b>&gt;</b>	R10	DOUGAN, G. et al. "Live Bacterial Vaccines and Their Application as Carriers for Foreign Antigens", Advances in Veterinary Science and Comparative Medicine, 1989, pp. 277-300, Vol. 33.					
~	R11	HOHMANN, E.L. et al. "Evaluation of a phoPlphoQ-deleted, aroA-deleted Live Oral Salmonella typhi Vaccine Strain in Human Volunteers", Vaccine, 1996, pp. 19-24, Vol. 14, No. 1.					
~	R12	LOWE, D.C. et al. "Characterization of Candidate Live Oral Salmonella typhi Vaccine Strains Harboring Defined Mutations in aroA, aroC, and htrA", Infection and Immunity, 1999, pp. 700-707, Vol. 67, No. 2.					
N	R13	SCHODEL, F. et al. "Hepatitis B Virus Nucleocapsid/pre-S2 Fusion Proteins Expressed in Attenuated Salmonella for Oral Vaccination", Journal of Immunology, 1990, pp. 4317-4321, Vol. 145, No. 12.					

Examiner			Date
Signature	MARK	NAVARRO	
Signature	1 1000		

\*EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through cliation if not in conformance

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to the property of the public which is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute	for form 1449B/P	то		Complete If Known			
	RMATION		LIDE	Application Number	10/822,053		
	EMENT B			Filing Date	April 8, 2004		
UIAII	-INCIAI D	APPLIC	ANI	First Named Inventor	Robert Graham Feldman		
(use	as many shee	ts as necessar	ν)	Group Art Unit	1645		
				Examiner Name	NAVRERO		
Sheet	3	of	3	Attorney Docket Number	GJE-44D1		

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>			
m	R14	PLOTKIN, S. A. <u>Vaccines,</u> 1988, p. 571, W.B Saunders Co., Philadelphia.	Ţ			
	_R15					
	R16					
-	R17					
	R18	·				
•	R19					
	R20					
	R21					
	R22					
	R23					
	R24					
	R25					
	R26	<u> </u>	1			

Examiner				
Cxaminer			Date	
Signature	MARIC	NAVIERS		11/2 /
EXAMINER: Initial	if reference considered	unbadhas as as A sit if	Considered	11/29/05

dered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select ontion 2.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.